Encouraged by previously published reports demonstrating synergistic interactions between EGFR and mTOR inhibitors in various cancers [34-36] we investigated the activity of the EGFR targeted drug gefitinib used in combination with a rapamycin analog, RAD001, in HER2 overexpressing and EGFR co-expressing breast cancer models with TZ sensitive or resistant phenotypes [12,38,42,43]. Here, ERBB2 is linked to breast cancer.